Printer Friendly

Browse Pharmaceutical biotechnology topic

Articles

1-96 out of 96 article(s)
Title Author Type Date Words
AgeX Therapeutics and ImStem biotechnology Sign Non-Binding letter of intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS. Jun 2, 2020 660
ZYUS AND VIDO-INTERVAC DEVELOP VACCINE FOR COVID-19. May 27, 2020 489
ZYUS Collaborates with USask's VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19. May 8, 2020 277
Manufacturing Equipment Technology: The future of highly compliant, efficient equipment that's customized to suit a large variety of applications. Brooks, Kristin Mar 1, 2020 1986
Puma Biotechnology Receives US FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer. Feb 28, 2020 877
Bioasis Technologies Inc proposes extension and repricing of warrants. Jan 30, 2020 159
Bioasis reports departure of board director Nancy Stagliano. Nov 26, 2019 131
Bioasis reports departure of board director Nancy Stagliano. Nov 26, 2019 127
Stone Capital collaborates with Biosyngen. Nov 12, 2019 122
Stone Capital collaborates with Biosyngen. Nov 12, 2019 118
Single-Use Technology: A Practical Guide to Design and Implementation, 2nd Edition. Brief article Oct 1, 2019 110
US FDA Accepts Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer. Sep 16, 2019 585
THIS IS THE PLACE FOR LIFE SCIENCES. Etherington, Rob Sep 1, 2019 230
Puma Biotechnology announces inducement awards two new non-executive employees. Jul 26, 2019 175
Puma Biotechnology Submits a Supplemental New Drug Application to US FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer. Jul 8, 2019 910
Puma Biotechnology Submits a Supplemental New Drug Application to US FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer. Jul 8, 2019 874
Palatin Technologies awarded FDA's orphan drug designation for PL-8177 for treatment of non-infectious uveitis. Jun 7, 2019 243
Palatin Technologies awarded FDA's orphan drug designation for PL-8177 for treatment of non-infectious uveitis. Jun 7, 2019 239
Bioasis Aims to Raise CDN 1m Via Private Placement. May 9, 2019 289
Bioasis Technologies Inc reports extension of warrant. Mar 26, 2019 137
Science magazine honours Regeneron Pharmaceuticals. Oct 29, 2018 139
Science magazine honours Regeneron Pharmaceuticals. Oct 29, 2018 135
2008: Biotechnology emerges and fosters the dramatic growth of specialty pharmacy. Oct 8, 2018 235
JMP Group adds managing director to expand investment banking division. Sep 27, 2018 205
JMP Group adds managing director to expand investment banking division. Sep 27, 2018 203
Shawn Cross joins JMP Securities as MD. Sep 27, 2018 234
DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS. Henry, Brandy Sep 22, 2018 6958
Qosina: Sterilization Supplies. Aug 23, 2018 136
Bioasis Closes CDN 972,722 Private Placement. Aug 15, 2018 321
Puma Biotechnology Files New Drug Submission for Nerlynx in Canada. Aug 1, 2018 331
Bioasis' Lead Candidate Increases Brain Neurochemicals in Pre-clinical Microdialysis Study. Jul 27, 2018 271
Palatin Technologies submits Bremelanotide NDA with US FDA for treating HSDD. Jun 5, 2018 250
Palatin Technologies submits Bremelanotide NDA with US FDA for treating HSDD. Jun 5, 2018 246
Generex Receives USD 700k Fee from Shenzhen BioScien Pharmaceuticals. Jan 3, 2018 310
ArmaGen Secures Fast Track Designation for Treatment of Hurler Syndrome. Dec 6, 2017 379
BioSpecifics Technologies posts lower net income of USD2.7m for Q3 2017. Financial report Nov 13, 2017 165
BioSpecifics Technologies posts lower net income of USD2.7m for Q3 2017. Financial report Nov 13, 2017 161
Puma Biotechnology Secures USD 100m Term Loan; Will Support Nerlynx Commercial Initiatives. Nov 6, 2017 221
Puma Biotechnology grants inducement wards to employees. Aug 28, 2017 209
AzarGen Biotechnologies wins European patent for application: PRODUCTION OF RECOMBINANT HUMAN SURFACTANT PROTEIN-B. Jul 26, 2017 199
FDA Advisory Committee Recommends Approval of Puma Biotechnology's Neratinib. May 26, 2017 331
California Life Sciences Association Backs Confirmation of Gottlieb as New US FDA Commissioner. May 9, 2017 328
US FDA Advisory Committee to Review Puma Biotechnology's NDA for Neratinib Early Stage Breast Cancer Treatment. Apr 18, 2017 346
Puma biotechnology Launches Expanded Investigational Therapy Access Programme for US Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers. Apr 4, 2017 330
2017 PDA Annual Meeting preview: learn about advanced therapeutic strategies and trends in process development and manufacturing. Apr 1, 2017 684
Palatin Technologies announces USPTO Notice of Allowance for Bremelanotide Methods for treating hypoactive sexual desire disorder. Mar 21, 2017 236
Palatin Technologies announces USPTO Notice of Allowance for Bremelanotide Methods for treating hypoactive sexual desire disorder. Mar 21, 2017 232
INTERPHEX preview: What's on tap for 2017. Botta, Mike Mar 1, 2017 862
Packaging equipment technology trends: Biopharma trends drive advanced equipment capabilities. Brooks, Kristin Mar 1, 2017 1747
Oxeia Biopharmaceuticals adds new Advisory Board member. Dec 15, 2016 165
Oxeia Biopharmaceuticals adds new Advisory Board member. Dec 15, 2016 161
Puma Biotechnology prices public offering at USD40.00 per share. Oct 20, 2016 163
Puma Biotechnology prices public offering at USD40.00 per share. Oct 20, 2016 159
Dynavax's HEPLISAV-B accepted for review by VBRPAC. Aug 8, 2016 244
Dynavax's HEPLISAV-B accepted for review by VBRPAC. Aug 8, 2016 240
Palatin Technologies raises USD9.2m from issue of units. Aug 5, 2016 199
Palatin Technologies raises USD9.2m from issue of units. Aug 5, 2016 195
Palatin Technologies anticipates USD9.25m from offering of units. Aug 2, 2016 289
Palatin Technologies anticipates USD9.25m from offering of units. Aug 2, 2016 285
biOasis wins another US Patent for the delivery of therapeutic agents across the blood-brain barrier. Jul 11, 2016 144
biOasis wins another US Patent for the delivery of therapeutic agents across the blood-brain barrier. Jul 11, 2016 140
InstantGMP PRO: Game-Changing Software for Pharmaceutical and Biotech Manufacturing. Jun 10, 2016 232
Acticor Biotech chooses Catalent's GPEx technology. Apr 1, 2016 256
Portage Biotech and Biohaven Pharmaceutical sign contract with ALS Biopharma and Fox Chase Chemical Diversity Center. Oct 5, 2015 211
Portage Biotech and Biohaven Pharmaceutical sign contract with ALS Biopharma and Fox Chase Chemical Diversity Center. Oct 5, 2015 207
Biopharming: Next big thing? Jun 22, 2015 741
Paras Biopharmaceuticals Wins International Award. Dec 11, 2014 607
The FDA and 23andMe: violating the first amendment or protecting the rights of consumers? Baudhuin, Linnea M. Jun 1, 2014 1912
Ligand Pharmaceuticals Incorporated and Azure Biotech partnership to develop lasofoxifene targeting womena[euro](tm)s health. Jul 23, 2013 186
Ligand Pharmaceuticals Incorporated and Azure Biotech partnership to develop lasofoxifene targeting womena[euro](tm)s health. Jul 23, 2013 182
UMN Pharma signs collaboration agreement with Catalent Pharma Solutions. Dec 17, 2012 117
UMN Pharma signs collaboration agreement with Catalent Pharma Solutions. Dec 17, 2012 113
Sartorius opens Guxhagen bioreactor facility. Oct 1, 2012 117
Greiner Bio-One North America offers solutions in biotechnology, diagnostics, and pharmaceuticals. Lenhoff, Alan Aug 1, 2012 993
Sartorius Stedim North America Inc. Company overview May 1, 2012 281
Catalent, Nascent to develop antibodies. May 1, 2012 224
Project, product or company. Boni, Arthur A. Report Apr 1, 2012 3180
Pacgen Biopharmaceuticals raises CAD300,000 from private placement. Jan 26, 2012 152
Bioscience. May 1, 2011 389
Sartorius Stedim North America Inc. Company overview Dec 15, 2010 311
EpiCept Corp to give presentation at NYSSA Biotech and Specialty Pharmaceuticals Conference. Conference news Nov 26, 2010 128
Getting your fill: aseptic filling technologies adapt as biopharmaceutical products grow in importance. Auerbach, Mike Aug 1, 2010 1284
What about know-how: heightened obviousness and lowered disclosure is not a panacea to the American patent system for biotechnology medication and pharmaceutical inventions in the post-KSR era. Su, Yi-Chen Jun 22, 2010 18993
Sartorius Stedim North America Inc. Company overview Jun 1, 2010 281
M+W Group at the AchemaAsia Show in Beijing: Integrated Solutions for Pharmaceutical, Biotech, Chemical, Food & Beverages, Nutritional, Microelectronic and PV Industries. May 28, 2010 543
Biotechnological innovation and partnerships. Gold, E. Richard Jan 1, 2010 7112
Catalent Pharma Solutions. Company overview Dec 15, 2009 402
Sartorius Stedim North America Inc. Company overview Dec 15, 2009 314
The adoption of SPR in drug discovery and development. Report Sep 1, 2009 1487
Biotechnology business models work: evidence from the pharmaceutical marketplace. Glick, J. Leslie Report Apr 1, 2008 6794
Biogenerics 2007: how far have we come? Tucker, John; Yakatan, Seth; Yakatan, Stan Report Nov 1, 2007 5137
Biotech drugs drive growth in spending. Brief article May 21, 2007 215
FDA chief opposes routine approval of biotech generics. Brief article Mar 12, 2007 171
The promise of biotechnology for bioprocess engineers. Cundiff, John Sep 1, 2003 1163
Designing bioreactors: thinking in and out of a box. (Focus on Biological Engineering). Cuello, Joel L. May 1, 2003 544
Linking technological change to business needs: roadmapping offers a systematic approach for the pharmaceutical-biotechnology industry to target technology investments in the drug delivery process. McCarthy, Robert C. Mar 1, 2003 3734

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters